Skip to main content

Day: January 25, 2022

Biotalys Achieves Breakthrough in Protein Expression Increasing Commercial Potential for its first BioFungicide Evoca

Next generation of Evoca products provides commercial potential at 2026 horizon Ghent, Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE) — Press release Biotalys Achieves Breakthrough in Protein Expression Increasing Commercial Potential for its first BioFungicide Evoca Next generation of Evoca products provides commercial potential at 2026 horizon Ghent, BELGIUM – 25 January 2022, 07:00 CET – Biotalys (Euronext – BTLS), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, today announced it has achieved a breakthrough in protein expression of the bioactive ingredient of its first biocontrol product Evoca™*. The breakthrough announced today has the potential to transform Evoca from a market calibration tool into a product providing commercial value at competitive efficacy and...

Continue reading

Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)

Interim data submitted to the FDA show majority of pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowing Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting,...

Continue reading

Nexus REIT Announces January and February Distributions

TORONTO and MONTREAL, Jan. 24, 2022 (GLOBE NEWSWIRE) — Nexus Real Estate Investment Trust (TSX: NXR.UN) (“Nexus” or the “REIT”) announced today the declaration of the January and February 2022 distributions. The REIT will make a cash distribution in the amount of $0.05333 per unit, representing $0.64 per unit on an annualized basis, payable February 15, 2022 to unitholders of record as of January 31, 2022. The REIT will also make a cash distribution in the amount of $0.05333 per unit, representing $0.64 per unit on an annualized basis, payable March 15, 2022 to unitholders of record as of February 28, 2022. The REIT’s distribution reinvestment plan (“DRIP”) entitles eligible unitholders to elect to receive all, or a portion of the cash distributions of the REIT reinvested in units of the REIT. Eligible unitholders who so elect...

Continue reading

Keyarch Acquisition Corporation Announces Pricing of $100 Million Initial Public Offering

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) — Keyarch Acquisition Corporation (the “Company”) announced today that it priced its initial public offering of 10,000,000 units at a price of $10.00 per unit. The Company has granted the underwriters a 45-day option to purchase up to 1,500,000 units to cover over-allotments, if any. The units are expected to commence trading on January 25, 2022 on The Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “KYCHU.” Each unit consists of one Class A ordinary share of the Company, one-half of one redeemable warrant and one right to receive one-tenth of one Class A ordinary share. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the...

Continue reading

Surge Copper Announces Annual Grant of Equity Incentive Awards

Vancouver, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQX: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) announces that it has awarded a total of 5,611,843 restricted share units to various employees, executives, directors, and consultants of the Company on the basis of the 5-day volume-weighted average price on the TSX Venture Exchange and pursuant to a new Share Compensation Plan to be approved by shareholders at an upcoming shareholders’ meeting. A portion of the restricted share units vest based on the underlying share price performance over a three-year measurement period from the award date. A further portion of the restricted share units will vest annually over a three-year period from the award date. A further portion of the restricted share units was granted to Non-Executive...

Continue reading

WisdomTree Comments on Filing by ETFS Capital Limited

No Shareholder Action Required at This Time NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) — WisdomTree Investments, Inc. (NASDAQ: WETF), an exchange-traded fund (“ETF”) and exchange-traded product (“ETP”) sponsor and asset manager, today issued the following statement in response to the Schedule 13D filed today with the U.S. Securities and Exchange Commission by WisdomTree shareholder ETFS Capital Limited: The WisdomTree Board of Directors welcomes and encourages open communications with its shareholders and values their input. We are committed to enhancing value for all shareholders and will continue to take actions that we believe will enable us to achieve this objective. Our shareholders need take no action at this time. Advisors Goodwin Procter LLP is serving as legal counsel to WisdomTree. Innisfree M&A is serving as proxy...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.